隴神戎發(300534.SZ):宣肺止嗽合劑的競爭優勢在於止咳效果顯著、起效快、療程短
格隆匯7月27日丨有投資者向隴神戎發(300534.SZ)提問:元胡止痛滴丸和宣肺止嗽合劑的主要競品有哪些?公司產品的優勢在哪?
隴神戎發回復:元胡止痛滴丸的公司主打產品元胡止痛滴丸的主要競爭產品為元胡止痛類藥物的片劑、膠囊劑、顆粒劑等其他劑型;宣肺止嗽合劑的主要競品包括念慈庵蜜煉川貝枇杷膏、肺寧顆粒、川貝枇杷糖漿、金銀花口服液、清熱止咳合劑等。
元胡止痛滴丸的競爭優勢在於滴丸劑自身生物利用度高、起效快、不成癮、毒副作用小;宣肺止嗽合劑的競爭優勢在於止咳效果顯著、起效快、療程短。上述產品相比於競品具有一定的競爭優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.